Dopamine D2‐type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Oxidative stress, a process in which neurotoxic oxygen free radicals cause dopaminergic neuronal degeneration, has been implicated in the degenerative process in Parkinson's disease. Glutamate‐induced neurotoxicity is a model of oxidative stress. We demonstrated that preincubation with D2‐type dopamine agonists bromocriptine and quinpirole provides neuroprotection against glutamate‐induced neurotoxicity in cultured rat mesencephalic neurons. Simultaneous administration of D2 agonists, however, did not provide neuroprotection. The protective effects were dependent on the duration of preincubation and were blocked by a D2 antagonist and a protein synthesis inhibitor. Furthermore, preincubation with D2 agonists provided neuroprotection against toxicity induced by calcium overload and exposure to superoxide anions. Confocal microscopic analysis, using 2,7‐dichlorofluorescin diacetate, revealed that bromocriptine preincubation suppressed the action of radicals on neurons. These findings indicate that dopamine D2 agonists provide protection mediated not only by the inhibition of dopamine turnover but also via D2‐type dopamine receptor stimulation and the subsequent synthesis of proteins that scavenge free radicals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Reactive Oxygen Species and the Central Nervous System
Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947
LeBel, C. P., Ischiropoulos, H., & Bondy, S. C. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00026a012 · Cited by 2,689
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Van Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
Sunahara, R. K., Guan, H.-C., O'Dowd, B. F., Seeman, P., Laurier, L. G., Ng, G., George, S. R., Torchia, J., Van Tol, H. H. M., & Niznik, H. B. (1991) · Nature · doi:10.1038/350614a0 · Cited by 1,165
Cloning and expression of a rat D2 dopamine receptor cDNA
Bunzow, J. R., Tol, H. H. M. V., Grandy, D. K., Albert, P., Salon, J., Christie, M., Machida, C. A., Neve, K. A., & Civelli, O. (1988) · Nature · doi:10.1038/336783a0 · Cited by 1,117
Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures
Dawson, V., Dawson, T., Bartley, D., Uhl, G., & Snyder, S. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-06-02651.1993 · Cited by 1,014
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Glutamate neurotoxicity in cortical cell culture is calcium dependent
Choi, D. W. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90069-2 · Cited by 810
Cited by
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
Henchcliffe, C., & Beal, M. F. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0924 · Cited by 783
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Davidson, C., Gow, A. J., Lee, T. H., & Ellinwood, E. H. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00054-6 · Cited by 521
The pathogenesis of cell death in Parkinson's disease
Jenner, P., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 446
Glaucoma as a neurodegenerative disease
Gupta, N., & Yücel, Y. H. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3280895aea · Cited by 422
Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Shibasaki, H., Kume, T., & Akaike, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008035200 · Cited by 415
Self-citationSalazar, J., Mena, N., Hunot, S., Prigent, A., Alvarez-Fischer, D., Arredondo, M., Duyckaerts, C., Sazdovitch, V., Zhao, L., Garrick, L. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804373105 · Cited by 409
ESPOSITO, E., ROTILIO, D., DIMATTEO, V, DIGIULIO, C., CACCHIO, M., & ALGERI, S. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00078-7 · Cited by 326
Beckhauser, T. F., Francis-Oliveira, J., & De Pasquale, R. (2016) · Journal of Experimental Neuroscience · doi:10.4137/jen.s39887 · Cited by 301
Calabrese, V., Bates, T. E., & Stella, A. M. G. (2000) · Neurochemical Research · doi:10.1023/a:1007604414773 · Cited by 284
Le, W.-D., Rowe, D., Xie, W., Ortiz, I., He, Y., & Appel, S. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08447.2001 · Cited by 275
Aquilano, K., Baldelli, S., Rotilio, G., & Ciriolo, M. R. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9697-6 · Cited by 265
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218
Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility
Chen, J. Y., Wang, E. A., Cepeda, C., & Levine, M. S. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00114 · Cited by 174
“For example, activation of D2 receptors by quinpirole reduces the toxicity of both NMDA and kainic acid in rat striatal neurons (Cepeda and Levine, 1998), as well as in mesencephalic and cortical neurons (Sawada et al., 1998; Kihara et al., 2002).”
BackgroundSlowing Parkinson’s disease progression: Recent dopamine agonist trials
Ahlskog, J. E. (2003) · Neurology · doi:10.1212/01.wnl.0000044047.58984.2f · Cited by 161
Calcium signaling alterations, oxidative stress, and autophagy in aging
Ureshino, R. P., Rocha, K. K., Lopes, G. S., Bincoletto, C., & Smaili, S. S. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5777 · Cited by 143
Neurotrophic factors in Parkinson’s disease are regulated by exercise: Evidence-based practice
da Silva, P. G. C., Domingues, D. D., de Carvalho, L. A., Allodi, S., & Correa, C. L. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.02.017 · Cited by 87
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
“Numerous in vitro and in vivo laboratory studies have shown neuroprotective potential of dopaminergic agonists that can be mediated via several mechanisms including free radical scavenging [149, 221], and anti-oxidative properties [352, 453].”
Background
Metadata
- Authors
- Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Akaike, A., Kimura, J., & Shimohama, S.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1998-07
- Volume
- 44
- Issue
- 1
- Pages
- 110-119
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1993336124
- Cited by
- 193
- References
- 50
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.